TCT-715 Developing of a TAVR risk score for the prediction of mortality after transcatheter aortic valve replacement  by Figulla, Hans R. et al.
Outcomes
LOTUS
(n¼46)
CoreValve
(n¼46) P-Value
Device Success 43 (93.5%) 33 (71.7%) 0.006
No Procedural Mortality 46 (100%) 46 (100%) 1.00
Correct Position of 1 Device 46 (100%) 45 (97.8%) 0.32
Mean Gradient <20mmHg 44 (95.6%) 46 (100%) 0.16
No More than Mild AR 45 (97.8%) 35 (76.1%) 0.004
Pericardial Effusion/Tamponade 1 (2.2%) 1 (2.2%) 1.00
New Pacemaker 14 (30.4%) 8 (17.4%) 0.14
Vascular Injury Minor 13 (28.3%) 14 (30.4%) 0.82
Major 5 (10.9%) 3 (6.5%) 0.74
Major Disabling Stroke 2 (4.3%) 1 (2.2%) 0.56
Peri-procedural Myocardial Infarction 0 (0%) 2 (4.3%) 0.50
Death within 30
days
Non-
Cardiovascular
0 (0%) 1 (2.2%) 0.32
Cardiovascular 1 (2.2%) 2 (4.3%) 0.56
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comResults: In total 662 patients were included, with a mean age of 82 years and 52%
were female. MACCE at 30 days occurred in 12% patients treated with aspirin only
(ASA) and in 15% of the patients treated with DAPT (p¼ 0.31). With regards to
individual outcomes no signiﬁcant difference was observed between ASA and DAPT
treatment groups; all-cause mortality (3.9% vs. 4.7%, p¼ 0.62), ACS (0.3% vs. 0.4%,
p ¼ 0.73), stroke (1.5% vs. 2.4%, p ¼ 0.40) and life threatening or major bleeding
(7.6% vs. 11.8%, p ¼ 0.07).
Conclusions: Treatment with ASA one month following TAVI was not associated
with an increased MACCE rate. Moreover, a (non-signiﬁcant) trend for less life
threatening and major bleeding was observed in the ASA treatment group.
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Background: Retrievability and repositionability are two characteristics of the Direct
Flow Medical (DFM) valve that are conceived to reduce post-transcatheter aortic
valve replacement (TAVI) aortic regurgitation, which has been strongly associated to
clinical outcome. In the present study, we sought to assess the performance of the
DFM prosthesis in a multicenter, real-world experience and to compare these results
with the DISCOVER trial ﬁndings.
Methods: In this multicenter, prospective, real-world experience, 105 high-risk pa-
tients (Logistic Euroscore: 24.714.7) with severe aortic stenosis were prospectively
enrolled and underwent TAVI with DFM prosthesis.
Results: No signiﬁcant differences emerged comparing the baseline risk proﬁle be-
tween this real-world experience and the DISCOVER trial. Initial positioning and
repositioning led to a ﬁnal reduction of the initial trans-aortic gradient by 4515 mmHg
with amean residual gradient of 94mmHg. In 98% of cases there was no or only trivial
aortic regurgitation after implantation (Grade 0 or 1). The VARC-2-deﬁned device
success was 98% (vs. 91% in the DISCOVER trial; p¼0.03). Ten patients (10%) un-
derwent permanent pacemaker implantation due to post-procedural persistent advanced
atrio-ventricular block (vs 17% in the DISCOVER trial; p¼0.148). In 6% of cases
device retrieval was successfully performed during the procedure. At 30 day follow up
the survival rate was 98% (two deaths), with a patient safety event rate of 89%.
Conclusions: In a multicenter, prospectively enrolled, high-risk patient population
with severe aortic stenosis, the DFM retrievable and repositionable prosthesis
demonstrated excellent short-term efﬁcacy and safety. Despite similar risk proﬁle,
real-world experience reached a signiﬁcantly higher device success rate in comparison
with the DISCOVER trial.
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Background: Based on data from the German Aortic Valve Registry (GARY) a novel
scoring system to predict 1year-mortality in patients undergoing transcatheter aortic
valve replacement was developed.
Methods: 3875 pt undergoing TAVR were included national multicenter registry.
One year mortality after TAVR was chosen as a binary outcome measure. First,
potential risk factors were tested in an univariate manner by Fisher’s exact test for
signiﬁcant inﬂuence on mortality and multiple logistic regression with backward and
forward selection. Calibration was ascertained by the Hosmer-Lemeshow method. In
order to deﬁne the quality of discrimination, the area under the receiver operating
characteristic (ROC) curve was calculated.
Results: In 3772 of 3875 (97.3%) pts. survival status was known and in 3221 (85.4%)
pts a complete data set was available. One-year mortality was 22..7% (n¼730) for all
patients. Based on multiple logistic regression, 22 risk factors impacting mortality
were identiﬁed, including age, body mass index and left ventricular function cate-
gorized in two (left ventricular function) or three subgroups (age). The area under the
ROC curve with a value of 0.712 afﬁrmed the quality of discrimination of the
established scoring model.
Conclusions: Based on GARY data the above model allows the prediction of 1-year
mortality after TAVR, thus supporting continuous improvement of patient selction for
interventional aortic valve procedures.B210 JACC Vol 64/11/Suppl B j SepTCT-716
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Background: New generation TAVR devices offer a number of potential advantages
such as retrievability, re-positionability, outer sealing mechanisms and in some cases
lower proﬁle. To date, however, there remain no published comparisons between ﬁrst
generation devices and these new generation prostheses.
Methods: We compare 46 patients who received a LOTUS prosthesis (Boston Sci-
entiﬁc, MA, USA) with 46 contemporary patients implanted with a CoreValve device
(Medtronic, MN, USA) at a single Australian centre between December 2009 and
March 2014. Transthoracic echocardiographic assessment was performed at discharge
and 30 days following implantation with echocardiographic outcomes independently
assessed by a core laboratory.
Results: Mean age at enrolment was 84.024.97 years in the LOTUS cohort and
82.504.95 years in the CoreValve group. Procedural risk scores were similar be-
tween cohorts (STS: 5.522.04 vs 5.102.53, p¼0.38) as was frailty (Charlson In-
dex: 2.722.09 vs 2.741.44, p¼0.95). Comorbidities of T2DM (19.6% vs 19.6%),
existing coronary artery disease (60.9% vs 65.2%), peripheral vascular disease (6.6%
vs 13.2%) and airways disease (30.4% vs 28.3%) were not different between cohorts.
Procedure duration (119.340.3 vs 111.337.2min, p¼0.88), device duration
(28.219.0 vs 13.614.8min, p¼0.73) and contrast volume used (221.582.9 vs
254.489.7mL, p¼0.60) were not different between cohorts.Conclusions: The second-generation LOTUS transcatheter prosthesis may be asso-
ciated with higher VARC2 deﬁned device success, driven predominantly by less re-
sidual AR. Core laboratory adjudicated echocardiographic assessment of residual
aortic regurgitation, effective oriﬁce area and trans-prosthesis gradient at discharge
and 30 days will be presented.
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Background: Coronary ﬂow velocity reserve (CVR) is reduced in patients with se-
vere symptomatic aortic stenosis, contributing to ischemic clinical symptoms. We
evaluated coronary ﬂow dynamics assessed by intracoronary Doppler surveillance of
the blood ﬂow in the left anterior descending (LAD) artery during the entire trans-
femoral TAVI procedure.
Methods: 15 high-risk patients with severe, symptomatic aortic valve stenosis
(Age 7945yrs; EuroScore174%), who underwent TAVI using the Edwards bio-
prosthesis were included in the study, its main exclusion criterion being presence of a
LAD stenosis. Peak hyperemic ﬂow conditions were determined by intracoronary
bolus injection of adenosine. CVR was computed as the ratio of hyperemic average
peak velocity (hAPV) to baseline average peak velocity (bAPV). CVR was assessed attember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
